|
2024-05-09 |
2024-05-07 |
S
Sale
|
Tourangeau Greg
Principal Accounting Officer
Officer
|
236
-2.0%
7.76
USD 1,831
|
236
-2.0%
|
7.76
|
USD 1,831
|
|
|
2024-03-08 |
2024-03-08 |
PS
Planned sale
|
Tourangeau Greg
Vice President, Finance
Officer
|
4,884
-29.3%
11.72
USD 57,219
|
4,884
-29.3%
|
11.72
|
USD 57,219
|
|
|
2024-03-05 |
2024-03-04 |
B
Purchase
|
Sapir Alex
See Remarks
Executive Director
|
43,360
+inf%
11.35
USD 492,028
|
43,360
+inf%
|
11.35
|
USD 492,028
|
|
|
2023-05-11 |
2023-05-10 |
S
Sale
|
Tourangeau Greg
Principal Accounting Officer
Officer
|
210
-1.3%
3.31
USD 695
|
210
-1.3%
|
3.31
|
USD 695
|
|
|
2023-01-24 |
2023-01-20 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
1,923,076
+19.9%
13.00
USD 24,999,988
|
1,923,076
+19.9%
|
13.00
|
USD 24,999,988
|
|
|
2023-01-13 |
2023-01-13 |
PS
Planned sale
|
Gould Robert J
Interim President & CEO
Executive Director
|
6,766
-1.3%
15.00
USD 101,490
|
6,766
-1.3%
|
15.00
|
USD 101,490
|
|
|
2023-01-06 |
2023-01-04 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
58,369
+0.6%
7.80
USD 455,091
|
58,369
+0.6%
|
7.80
|
USD 455,091
|
|
|
2023-01-06 |
2023-01-04 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
122,334
+1.3%
7.03
USD 859,714
|
122,334
+1.3%
|
7.03
|
USD 859,714
|
|
|
2022-12-29 |
2022-12-27 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
4,089
+0.0%
5.99
USD 24,510
|
4,089
+0.0%
|
5.99
|
USD 24,510
|
|
|
2022-12-21 |
2022-12-19 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
98,787
+1.1%
5.90
USD 582,814
|
98,787
+1.1%
|
5.90
|
USD 582,814
|
|
|
2022-12-16 |
2022-12-16 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
1,341,420
+16.6%
5.42
USD 7,269,826
|
1,341,420
+16.6%
|
5.42
|
USD 7,269,826
|
|
|
2022-12-16 |
2022-12-15 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
237,029
+3.0%
5.50
USD 1,302,474
|
237,029
+3.0%
|
5.50
|
USD 1,302,474
|
|
|
2022-12-16 |
2022-12-14 |
B
Purchase
|
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
|
824,600
+11.8%
5.46
USD 4,501,574
|
824,600
+11.8%
|
5.46
|
USD 4,501,574
|
|
|
2022-06-08 |
2022-06-07 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
71,435
-12.4%
8.09
USD 577,895
|
71,435
-12.4%
|
8.09
|
USD 577,895
|
|
|
2022-06-06 |
2022-06-06 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
24,382
-4.6%
8.10
USD 197,592
|
24,382
-4.6%
|
8.10
|
USD 197,592
|
|
|
2022-06-06 |
2022-06-03 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
25,551
-4.8%
7.95
USD 203,056
|
25,551
-4.8%
|
7.95
|
USD 203,056
|
|
|
2022-06-06 |
2022-06-02 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
16,689
-3.2%
7.92
USD 132,162
|
16,689
-3.2%
|
7.92
|
USD 132,162
|
|
|
2022-04-11 |
2022-04-07 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
5,631
-1.1%
24.02
USD 135,228
|
5,631
-1.1%
|
24.02
|
USD 135,228
|
|
|
2022-04-05 |
2022-04-05 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
52,552
-9.4%
24.26
USD 1,274,775
|
52,552
-9.4%
|
24.26
|
USD 1,274,775
|
|
|
2022-04-05 |
2022-04-04 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
7,235
-1.4%
24.02
USD 173,749
|
7,235
-1.4%
|
24.02
|
USD 173,749
|
|
|
2022-04-05 |
2022-04-01 |
PS
Planned sale
|
Gould Robert J
Non-Executive Director
|
34,464
-6.4%
24.03
USD 828,160
|
34,464
-6.4%
|
24.03
|
USD 828,160
|
|
|
2021-08-12 |
2021-08-11 |
PS
Planned sale
|
Stuart Bryan
See Remarks
Executive Director
|
28,000
-100.0%
23.75
USD 665,000
|
28,000
-100.0%
|
23.75
|
USD 665,000
|
|
|
2021-08-12 |
2021-08-10 |
PS
Planned sale
|
Stuart Bryan
See Remarks
Executive Director
|
32,000
-100.0%
17.50
USD 560,000
|
32,000
-100.0%
|
17.50
|
USD 560,000
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Oltmans Curtis Gale
SVP, General Counsel
Officer
|
1,088
+inf%
9.01
USD 9,803
|
1,088
+inf%
|
9.01
|
USD 9,803
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,300
+inf%
9.00
USD 20,700
|
2,300
+inf%
|
9.00
|
USD 20,700
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
Morabito Christopher
Chief Medical Officer
Officer
|
1,100
+inf%
9.16
USD 10,076
|
1,100
+inf%
|
9.16
|
USD 10,076
|
|
|
2021-06-29 |
2021-06-28 |
B
Purchase
|
GERAGHTY JAMES A
Non-Executive Director
|
10,000
+12.4%
9.16
USD 91,600
|
10,000
+12.4%
|
9.16
|
USD 91,600
|
|
|
2021-03-17 |
2021-03-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
789
-0.2%
12.43
USD 9,806
|
789
-0.2%
|
12.43
|
USD 9,806
|
|
|
2021-03-17 |
2021-03-15 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
9,211
-1.8%
12.13
USD 111,773
|
9,211
-1.8%
|
12.13
|
USD 111,773
|
|
|
2021-02-24 |
2021-02-22 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
5,000
-24.7%
14.72
USD 73,582
|
5,000
-24.7%
|
14.72
|
USD 73,582
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,673
-0.3%
14.56
USD 24,367
|
1,673
-0.3%
|
14.56
|
USD 24,367
|
|
|
2021-02-18 |
2021-02-16 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
6,542
-1.2%
14.19
USD 92,830
|
6,542
-1.2%
|
14.19
|
USD 92,830
|
|
|
2021-01-25 |
2021-01-21 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
6,607
-30.3%
14.00
USD 92,498
|
6,607
-30.3%
|
14.00
|
USD 92,498
|
|
|
2021-01-22 |
2021-01-20 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
10,000
-1.9%
12.08
USD 120,826
|
10,000
-1.9%
|
12.08
|
USD 120,826
|
|
|
2020-07-09 |
2020-07-08 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
2,951
-2.3%
20.00
USD 59,020
|
2,951
-2.3%
|
20.00
|
USD 59,020
|
|
|
2020-07-09 |
2020-07-08 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.00
USD 50,000
|
2,500
-0.5%
|
20.00
|
USD 50,000
|
|
|
2020-07-02 |
2020-07-01 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,071
-1.6%
18.30
USD 19,599
|
1,071
-1.6%
|
18.30
|
USD 19,599
|
|
|
2020-07-01 |
2020-06-30 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
141
-0.1%
20.00
USD 2,820
|
141
-0.1%
|
20.00
|
USD 2,820
|
|
|
2020-06-26 |
2020-06-25 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,459
-2.1%
22.00
USD 32,098
|
1,459
-2.1%
|
22.00
|
USD 32,098
|
|
|
2020-06-26 |
2020-06-25 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.80
USD 51,992
|
2,500
-0.5%
|
20.80
|
USD 51,992
|
|
|
2020-06-12 |
2020-06-10 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
401
-0.6%
22.00
USD 8,822
|
401
-0.6%
|
22.00
|
USD 8,822
|
|
|
2020-06-10 |
2020-06-09 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
156
-0.0%
20.00
USD 3,120
|
156
-0.0%
|
20.00
|
USD 3,120
|
|
|
2020-06-09 |
2020-06-05 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
3,433
-0.6%
20.17
USD 69,251
|
3,433
-0.6%
|
20.17
|
USD 69,251
|
|
|
2020-06-08 |
2020-06-05 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
451
-0.7%
20.18
USD 9,101
|
451
-0.7%
|
20.18
|
USD 9,101
|
|
|
2020-06-08 |
2020-06-04 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
226
-0.3%
20.05
USD 4,531
|
226
-0.3%
|
20.05
|
USD 4,531
|
|
|
2020-06-05 |
2020-06-04 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,300
-0.2%
20.04
USD 26,058
|
1,300
-0.2%
|
20.04
|
USD 26,058
|
|
|
2020-06-05 |
2020-06-03 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,500
-0.3%
20.13
USD 30,192
|
1,500
-0.3%
|
20.13
|
USD 30,192
|
|
|
2020-06-04 |
2020-06-03 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
338
-0.5%
20.18
USD 6,820
|
338
-0.5%
|
20.18
|
USD 6,820
|
|
|
2020-06-04 |
2020-06-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
45
-0.1%
20.00
USD 900
|
45
-0.1%
|
20.00
|
USD 900
|
|
|
2020-06-03 |
2020-06-02 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,797
-0.5%
20.00
USD 55,940
|
2,797
-0.5%
|
20.00
|
USD 55,940
|
|
|
2020-06-03 |
2020-06-01 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
5
-0.0%
20.00
USD 100
|
5
-0.0%
|
20.00
|
USD 100
|
|
|
2020-06-01 |
2020-05-29 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
200
-0.3%
20.04
USD 4,007
|
200
-0.3%
|
20.04
|
USD 4,007
|
|
|
2020-06-01 |
2020-05-29 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,390
-0.3%
20.08
USD 27,911
|
1,390
-0.3%
|
20.08
|
USD 27,911
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
600
-0.9%
20.00
USD 12,000
|
600
-0.9%
|
20.00
|
USD 12,000
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
2,232
-1.7%
20.00
USD 44,640
|
2,232
-1.7%
|
20.00
|
USD 44,640
|
|
|
2020-06-01 |
2020-05-28 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
1,919
-0.3%
20.01
USD 38,391
|
1,919
-0.3%
|
20.01
|
USD 38,391
|
|
|
2020-05-29 |
2020-05-27 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
448
-0.4%
20.00
USD 8,960
|
448
-0.4%
|
20.00
|
USD 8,960
|
|
|
2020-05-28 |
2020-05-26 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
412
-0.3%
20.00
USD 8,240
|
412
-0.3%
|
20.00
|
USD 8,240
|
|
|
2020-05-28 |
2020-05-26 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.5%
20.00
USD 50,000
|
2,500
-0.5%
|
20.00
|
USD 50,000
|
|
|
2020-05-12 |
2020-05-12 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,860
-2.7%
18.00
USD 33,480
|
1,860
-2.7%
|
18.00
|
USD 33,480
|
|
|
2020-05-12 |
2020-05-11 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
7,500
-26.3%
16.00
USD 120,000
|
7,500
-26.3%
|
16.00
|
USD 120,000
|
|
|
2020-03-02 |
2020-03-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
315
-0.5%
18.13
USD 5,710
|
315
-0.5%
|
18.13
|
USD 5,710
|
|
|
2020-03-02 |
2020-03-02 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
Officer
|
1,828
-2.7%
17.26
USD 31,545
|
1,828
-2.7%
|
17.26
|
USD 31,545
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
250
-0.9%
18.61
USD 4,653
|
250
-0.9%
|
18.61
|
USD 4,653
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,102
-6.8%
17.43
USD 36,643
|
2,102
-6.8%
|
17.43
|
USD 36,643
|
|
|
2020-02-26 |
2020-02-24 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
Officer
|
2,648
-7.9%
16.18
USD 42,857
|
2,648
-7.9%
|
16.18
|
USD 42,857
|
|
|
2020-02-20 |
2020-02-19 |
PS
Planned sale
|
Wallace Owen B.
Chief Scientific Officer
Officer
|
6,088
-4.6%
20.00
USD 121,760
|
6,088
-4.6%
|
20.00
|
USD 121,760
|
|
|
2020-02-20 |
2020-02-19 |
PS
Planned sale
|
Gould Robert J
See Remarks
Executive Director
|
2,500
-0.4%
20.00
USD 50,000
|
2,500
-0.4%
|
20.00
|
USD 50,000
|
|
|
2020-02-05 |
2020-02-03 |
PS
Planned sale
|
Cadavid Diego
SVP Clinical Development
|
2,143
-3.0%
17.33
USD 37,142
|
2,143
-3.0%
|
17.33
|
USD 37,142
|
|
|
2020-01-27 |
2020-01-23 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
|
262
-0.8%
18.05
USD 4,730
|
262
-0.8%
|
18.05
|
USD 4,730
|
|
|
2020-01-27 |
2020-01-23 |
PS
Planned sale
|
Thomson Peter G.
VP Finance & Accounting
|
4,738
-12.3%
17.17
USD 81,372
|
4,738
-12.3%
|
17.17
|
USD 81,372
|
|
|
2019-07-23 |
2019-07-22 |
B
Purchase
|
Sanofi
Large shareholder
|
93,750
+20.2%
16.00
USD 1,500,000
|
93,750
+20.2%
|
16.00
|
USD 1,500,000
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Large shareholder
|
5,000
+0.8%
14.50
USD 72,499
|
5,000
+0.8%
|
14.50
|
USD 72,499
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Large shareholder
|
10,000
+1.7%
14.50
USD 144,996
|
10,000
+1.7%
|
14.50
|
USD 144,996
|
|
|
2019-07-22 |
2019-07-22 |
B
Purchase
|
Casdin Capital, LLC
Large shareholder
|
125,000
+26.9%
16.00
USD 2,000,000
|
125,000
+26.9%
|
16.00
|
USD 2,000,000
|
|
